By Fineline Cube 
WuXi Biologics (HKG: 2269) announced a collaboration agreement with Guizhou Sinorda Biomedicineic Co., Ltd. to provide process development and manufacturing services for SND006, Sinorda’s in‑house developed bispecific antibody targeting autoimmune diseases such as inflammatory bowel disease (IBD). The partnership aims to advance preclinical pharmaceutical studies and clinical sample production, accelerating SND006’s path to clinical application.
Partnership Structure & Strategic Terms
| Item | Detail |
|---|---|
| Companies | WuXi Biologics (HKEX: 2269) / Guizhou Sinorda Biotechnology |
| Asset | SND006 (innovative bispecific antibody) |
| Indication | Autoimmune diseases (IBD) |
| WuXi’s Role | Process development, preclinical studies, clinical sample manufacturing |
| Sinorda’s Role | In‑house drug developer; retains global rights |
| Clinical Timeline | Planned filings in China and US in 2026 |
| Future Scope | Multi‑project collaboration from molecule discovery to clinical manufacturing |
| Status | In vitro functional validation completed |
Drug Profile & Competitive Advantage
- Mechanism: Bispecific antibody designed to target key pathways in IBD pathogenesis
- Market Need: IBD affects an estimated 5 million patients globally; China’s IBD market growing at 15% CAGR due to rising prevalence and biologics adoption
- Strategic Value: SND006 represents a next‑generation autoimmune therapy, potentially offering improved efficacy over current anti‑TNFα standards
- Manufacturing Edge: WuXi’s large‑scale biologics capabilities enable rapid scale‑up and global supply chain readiness
- Dual Filing Strategy: Concurrent China/US clinical filings position SND006 for first‑in‑class bispecific IBD therapy
Market Impact & Commercial Outlook
- China IBD Market: Valued at ¥8 billion (~US$1.1 billion) in 2025, projected to reach ¥15 billion by 2030
- Global Bispecific Market: Expected to exceed $20 billion by 2030, driven by oncology and autoimmune applications
- Revenue Potential: Analysts estimate ¥2–3 billion (US$280–420 million) peak China sales for SND006 if approved
- Strategic Validation: Partnership underscores WuXi’s leadership in CDMO services for complex biologics while supporting Sinorda’s innovative pipeline
- Next Steps: IND‑enabling studies underway; clinical trial applications expected H2 2026
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for SND006. Actual results may differ due to clinical trial outcomes, competitive dynamics, and regulatory review processes.-Fineline Info & Tech